Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riociguat in Incipient Pulmonary Vascular Disease
NCT05339087Phase 2Terminated
- Sponsor
- Heidelberg University
- Start
- Oct 2022
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of riociguat in pulmonary vascular disease (PVD), pulmonary arterial hypertension (PAH), sponsored by Heidelberg University. Started Oct 2022; status: terminated.
02
Drugs
riociguat
03
Conditions
pulmonary vascular disease (PVD)pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT05339087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05339087.